Travere Therapeutics, Inc. (TVTX)
Nasdaq · Healthcare · Biotechnology
$57.67+1.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.4B
- Forward P/E
- 10.2
- 52-week range
- $22.59 – $68.73
- 52-week change
- +123.25%
- EPS (trailing)
- −$0.74
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $491M (+110.45%)
- Net income
- −$25.5M
- Operating margin
- −12.8%
- Diluted EPS
- −$0.29
From the company’s annual report on SEC EDGAR.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc.
Headquarters: San Diego, United States · 497 employees · travere.com